Keith WardApr 21Kuria to present at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2025- Kuria to present positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and retina disease Kuria...
Keith WardApr 23, 2024Kuria announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024- Kuria team to present potency, selectivity, and positive preclinical proof-of-concept data for lead NRF2 activator for both cornea and...
Keith WardFeb 28, 2024Venture Connect Selects Kuria Therapeutics to Present at 2024 Company Showcase- Kuria's Chief Executive Officer Dr. Keith Ward to present company overview to premiere venture forum in the Southeast Kuria...
Keith WardJan 3, 2024NRF2 Review Article Published by Kuria Therapeutics in Current Opinion in Pharmacology
Keith WardDec 6, 2023Kuria's CEO and Development Officer to Attend Upcoming J.P. Morgan Healthcare Conference- Kuria's Chief Executive Officer and Chief Development Officer to share ophthalmic program updates and present corporate overview Kuria...
Keith WardNov 10, 2023Kuria Therapeutics Selected to Present at 2023 Southwest Venture Forum- Chief Development Officer Dave Flory to present corporate overview and review Kuria's development plans for diseases of the cornea and...